Loading clinical trials...
Loading clinical trials...
Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Conditions
Interventions
Abatacept
Dexamethasone
+2 more
Locations
3
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
St. Francis Hospital
East Hills, New York, United States
Good Samaritan Hospital
West Islip, New York, United States
Start Date
September 11, 2018
Primary Completion Date
November 21, 2022
Completion Date
November 6, 2024
Last Updated
March 4, 2025
NCT05312255
NCT04508790
NCT04640779
NCT04850599
NCT04756401
NCT05288062
Lead Sponsor
Roswell Park Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions